Sandhu Naemat, Navarro Victor
Division of Digestive Diseases and Transplantation Albert Einstein Healthcare Network Philadelphia PA.
Hepatol Commun. 2020 Mar 13;4(5):631-645. doi: 10.1002/hep4.1503. eCollection 2020 May.
Although drug-induced liver injury (DILI) is a rare clinical event, it carries significant morbidity and mortality, leaving it as the leading cause of acute liver failure in the United States. It is one of the most challenging diagnoses encountered by gastroenterologists. The development of various drug injury networks has played a vital role in expanding our knowledge regarding drug-related and herbal and dietary supplement-related liver injury. In this review, we discuss what defines liver injury, epidemiology of DILI, its biochemical and pathologic patterns, and management.
尽管药物性肝损伤(DILI)是一种罕见的临床事件,但它具有显著的发病率和死亡率,是美国急性肝衰竭的主要原因。它是胃肠病学家遇到的最具挑战性的诊断之一。各种药物损伤网络的发展在扩展我们对药物相关、草药和膳食补充剂相关肝损伤的认识方面发挥了至关重要的作用。在这篇综述中,我们讨论了肝损伤的定义、DILI的流行病学、其生化和病理模式以及管理。